BURLINGTON, Mass. — August 5, 2025 — Leads & Copy — Fractyl Health, Inc. (Nasdaq: GUTS) plans to offer shares of its common stock and pre-funded warrants in an underwritten public offering, subject to market conditions. Each share or warrant will be sold with accompanying common warrants.
The price of each pre-funded warrant will equal the price per share of common stock, minus $0.00001. Fractyl intends to grant underwriters an option to purchase up to 15% more shares or pre-funded warrants. Proceeds will support the Revita and Rejuva pipeline programs and general corporate purposes.
Ladenburg Thalmann & Co. Inc. is the sole book-running manager. A registration statement is on file with the SEC, and a prospectus supplement will be available on the SEC’s website.
This announcement is not an offer to sell securities. Fractyl Health focuses on metabolic therapeutics for obesity and type 2 diabetes.
Contacts:
Jessica Cotrone, Head of Corporate Communications, jcotrone@fractyl.com, 978.760.5622
Brian Luque, Head of Investor Relations and Corporate Development, IR@fractyl.com, 951.206.1200
Source: Fractyl Health
